Form 4: PureTech Health Reports Seaport Therapeutics IPO Conversion

PureTech Health discloses the automatic conversion of preferred stock holdings into common stock following Seaport Therapeutics' IPO.

Summary

• PureTech Health plc, through its subsidiary PureTech LYT, Inc., converted 40,000,000 shares of Series A-1, 8,421,052 shares of Series A-2, and 3,031,578 shares of Series B Preferred Stock into Common Stock.
• The conversion occurred on May 4, 2026, at a ratio of one-for-3.1407.
• Following the conversion, PureTech holds a total of 16,685,013 shares of Seaport Therapeutics, Inc. (SPTX) common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, administrative disclosure confirming the successful IPO of a portfolio company.

Positives

• Successful conversion of preferred holdings indicates the completion of Seaport Therapeutics' initial public offering.
• PureTech maintains a significant equity stake of 16,685,013 shares in the newly public entity.

Negatives

• None identified; this is a standard administrative filing following an IPO.

Risks

• Market volatility associated with newly public biotechnology companies.
• Concentration risk regarding the value of the Seaport Therapeutics investment.

Future Outlook

The filing does not provide forward-looking guidance, as it is a disclosure of past ownership changes.

Industry Context

StockSavvy.ai notes that this filing is a routine post-IPO disclosure common in the biotechnology sector, where venture-backed entities like PureTech convert preferred equity into common stock upon a liquidity event.

Comparison to Industry Standards

• The conversion ratio and structure are consistent with standard venture capital exit mechanics in the life sciences industry.

Related Party Transactions

• PureTech Health plc is the parent entity of PureTech LYT, Inc., which holds the shares.

Stakeholder Impact

• Shareholders of PureTech Health may see changes in the valuation of their portfolio due to the public listing of Seaport Therapeutics.

Next Steps

• Ongoing monitoring of Seaport Therapeutics' share price performance.

Key Dates

Keywords

Seaport Therapeutics, PureTech Health, SPTX, IPO, Form 4, Beneficial Ownership, Biotech